Sep 12, 2021
Dr. Hugh Rienhoff is the Founder and Chief Executive Officer at Imago BioSciences. He and his team are developing their lead asset bomedemstat for the treatment of myeloproliferative neoplasms (MPNs) which are rare blood cancers.
Hugh explains, "So MPNs, myeloproliferative neoplasms, are actually a family of diseases that include myelofibrosis, polycythemia vera, and essential thrombocythemia. And they're all characterized by an elevation of one element in the blood or another different cell type."
"But they're all related in the sense that they share a family of very limited mutations. And those mutations, in one of three genes, typically arise in patients who are in their 50s or 60s and those mutations occur in the blood stem cells."
"They're not hereditary, typically. They're what we call somatic mutations arising in blood stem cells. And they are called neoplastic diseases, which is a Greek name for cancer, but they typically are much more indolent than your typical bone marrow cancers, like leukemia, which are almost fulminant by comparison."
@Imagobiorx #ImagoBioSciences #MPN #MPNSM #EssentialThrombocythemia #myelofibrosis #bomedemstat #LSD1 #BloodCancer #RareDisease